TMB‑365/TMB‑380
Long‑acting dual‑antibody therapy for HIV‑1
Phase 2bActive
Key Facts
Indication
Long‑acting dual‑antibody therapy for HIV‑1
Phase
Phase 2b
Status
Active
Company
About TaiMed Biologics
TaiMed Biologics combines CD4‑targeted biologics with CDMO services to address HIV and autoimmune markets.
View full company profile